Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 712-724

  Zins, Karin ^a   Mogg, Maurice ^b   Schneeberger, Christian ^b   Abraham, Dietmar ^a   Schreiber, Martin ^b,c  

^a Medical University of Vienna   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; CYP19 aromatase; rs10046; rs2236722; SNP

Indexed keywords

AROMATASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; 3' UNTRANSLATED REGION; ERBB2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; AUSTRIA; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTRADIOL BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION SYSTEM; PREMENOPAUSE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; 3' UNTRANSLATED REGION; BREAST NEOPLASMS; CANCER STAGING; GENETICS; METABOLISM; MIDDLE AGED; ONSET AGE; PATHOLOGY; RISK; RISK FACTOR;

3' UNTRANSLATED REGIONS; AGE OF ONSET; ALLELES; AROMATASE; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PREMENOPAUSE; RECEPTOR, ERBB-2; RISK FACTORS;

EID: 84891848804     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15010712     Document Type: Article

References (33)

1. Germain, D. Estrogen carcinogenesis in breast cancer. Endocrinol. Metab. Clin. N. Am. 2011, 40, 473-484.
2. Bulun, S.E.; Zeitoun, K.; Sasano, H.; Simpson, E.R. Aromatase in aging women. Semin. Reprod. Endocrinol. 1999, 17, 349-358.
3. Corbin, C.J.; Graham-Lorence, S.; McPhaul, M.; Mason, J.I.; Mendelson, C.R.; Simpson, E.R. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc. Natl. Acad. Sci. USA 1988, 85, 8948-8952.
4. Bulun, S.E.; Sebastian, S.; Takayama, K.; Suzuki, T.; Sasano, H.; Shozu, M. The human CYP19 (aromatase P450) gene: Update on physiologic roles and genomic organization of promoters. J. Steroid. Biochem. Mol. Biol. 2003, 86, 219-224.
5. Toda, K.; Terashima, M.; Kawamoto, T.; Sumimoto, H.; Yokoyama, Y.; Kuribayashi, I.; Mitsuuchi, Y.; Maeda, T.; Yamamoto, Y.; Sagara, Y.; et al. Structural and functional characterization of human aromatase P-450 gene. Eur. J. Biochem. 1990, 193, 559-565.
6. Sebastian, S.; Bulun, S.E. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J. Clin. Endocrinol. Metab. 2001, 86, 4600-4602.
7. Yue, W.; Wang, J.P.; Hamilton, C.J.; Demers, L.M.; Santen, R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 1998, 58, 927-932.
8. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005, 26, 331-345.
9. Fasching, P.A.; Loehberg, C.R.; Strissel, P.L.; Lux, M.P.; Bani, M.R.; Schrauder, M.; Geiler, S.; Ringleff, K.; Oeser, S.; Weihbrecht, S.; et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res. Treat. 2008, 112, 89-98.
10. Huang, C.S.; Kuo, S.H.; Lien, H.C.; Yang, S.Y.; You, S.L.; Shen, C.Y.; Lin, C.H.; Lu, Y.S.; Chang, K.J. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. Oncologist 2008, 13, 751-760.
11. Long, J.R.; Kataoka, N.; Shu, X.O.; Wen, W.; Gao, Y.T.; Cai, Q.; Zheng, W. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol. Biomark. Prev. 2006, 15, 2115-2122.
12. Dunning, A.M.; Dowsett, M.; Healey, C.S.; Tee, L.; Luben, R.N.; Folkerd, E.; Novik, K.L.; Kelemen, L.; Ogata, S.; Pharoah, P.D., et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl. Cancer Inst. 2004, 96, 936-945.
13. Tworoger, S.S.; Chubak, J.; Aiello, E.J.; Ulrich, C.M.; Atkinson, C.; Potter, J.D.; Yasui, Y.; Stapleton, P.L.; Lampe, J.W.; Farin, F.M., et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol. Biomark. Prev. 2004, 13, 94-101.
14. Haiman, C.A.; Dossus, L.; Setiawan, V.W.; Stram, D.O.; Dunning, A.M.; Thomas, G.; Thun, M.J.; Albanes, D.; Altshuler, D.; Ardanaz, E., et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007, 67, 1893-1897.
15. Wang, L.; Ellsworth, K.A.; Moon, I.; Pelleymounter, L.L.; Eckloff, B.W.; Martin, Y.N.; Fridley, B.L.; Jenkins, G.D.; Batzler, A.; Suman, V.J., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res. 2010, 70, 319-328.
16. Lunardi, G.; Piccioli, P.; Bruzzi, P.; Notaro, R.; Lastraioli, S.; Serra, M.; Marroni, P.; Bighin, C.; Mansutti, M.; Puglisi, F. et al. Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. Breast Cancer Res. Treat. 2013, 137, 167-174.
17. Park, I.H.; Lee, Y.S.; Lee, K.S.; Kim, S.Y.; Hong, S.H.; Jeong, J.; Lee, H.; Ro, J.; Nam, B.H. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 2011, 68, 1263-1271.
18. Ferraldeschi, R.; Arnedos, M.; Hadfield, K.D.; A'Hern, R.; Drury, S.; Wardley, A.; Howell, A.; Evans, D.G.; Roberts, S.A.; Smith, I. et al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Res. Treat. 2012, 133, 1191-1198.
19. Chen, C.; Sakoda, L.C.; Doherty, J.A.; Loomis, M.M.; Fish, S.; Ray, R.M.; Lin, M.G.; Fan, W.; Zhao, L.P.; Gao, D.L. et al. Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China. Cancer Epidemiol. Biomark. Prev. 2008, 17, 3457-3466.
20. Ma, X.; Qi, X.; Chen, C.; Lin, H.; Xiong, H.; Li, Y.; Jiang, J. Association between CYP19 polymorphisms and breast cancer risk: Results from 10,592 cases and 11,720 controls. Breast Cancer Res. Treat. 2010, 122, 495-501.
21. Cai, Q.; Kataoka, N.; Li, C.; Wen, W.; Smith, J.R.; Gao, Y.T.; Shu, X.O.; Zheng, W. Haplotype analyses of CYP19A1 gene variants and breast cancer risk: Results from the Shanghai breast cancer study. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 27-32.
22. Kristensen, V.N.; Harada, N.; Yoshimura, N.; Haraldsen, E.; Lonning, P.E.; Erikstein, B.; Karesen, R.; Kristensen, T.; Borresen-Dale, A.L. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000, 19, 1329-1333.
23. Haiman, C.A.; Hankinson, S.E.; Spiegelman, D.; Brown, M.; Hunter, D.J. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 2002, 11, 215-216.
24. Ralph, D.A.; Zhao, L.P.; Aston, C.E.; Manjeshwar, S.; Pugh, T.W.; DeFreese, D.C.; Gramling, B.A.; Shimasaki, C.D.; Jupe, E.R. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 2007, 109, 1940-1948.
25. Zhang, L.; Gu, L.; Qian, B.; Hao, X.; Zhang, W.; Wei, Q.; Chen, K. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res. Treat. 2009, 114, 327-338.
26. Pineda, B.; Garcia-Perez, M.A.; Cano, A.; Lluch, A.; Eroles, P. Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: From a case-control to a meta-analysis of 20,098 subjects. PLoS One 2013, 8, e53902.
27. Buzdar, A.U.; Vergote, I.; Sainsbury, R. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J. 2004, 10, 211-217.
28. Thomas, H.V.; Key, T.J.; Allen, D.S.; Moore, J.W.; Dowsett, M.; Fentiman, I.S.; Wang, D.Y. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br. J. Cancer 1997, 76, 401-405.
29. Colomer, R.; Monzo, M.; Tusquets, I.; Rifa, J.; Baena, J.M.; Barnadas, A.; Calvo, L.; Carabantes, F.; Crespo, C.; Munoz, M. et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin. Cancer Res. 2008, 14, 811-816.
30. Proestling, K.; Hebar, A.; Pruckner, N.; Marton, E.; Vinatzer, U.; Schreiber, M. The Pro Allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk. PLoS One 2012, 7, e47325.
31. Taubenschuß, E.; Marton, E.; Mogg, M.; Frech, B.; Ehart, L.; Muin, D.; Schreiber, M. The L10P polymorphism and serum levels of transforming growth factor β1 in human breast cancer. Int. J. Mol. Sci. 2013, 14, 15376-15385.
32. The R Development Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2009.
33. Bender, R.; Lange, S. Adjusting for multiple testing-When and how? J. Clin. Epidemiol. 2001, 54, 343-349.